Log In
BCIQ
Print this Print this
 

SOR-C27

  Manage Alerts
Collapse Summary General Information
Company Soricimed Biopharma Inc.
DescriptionTransient receptor potential vanilloid 6 (TRPV6) inhibitor derived from soricidin, the paralytic peptide in shrew saliva.
Molecular Target Transient receptor potential vanilloid 6 (TRPV6)
Mechanism of ActionTransient receptor potential vanilloid 6 (TRPV6) inhibitor
Therapeutic ModalityPeptide
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat breast and ovarian cancer; Treat cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/23/2012

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today